

Transient Elastography (Fibroscan) in Patients with Non-cirrhotic Portal Fibrosis

Praveen Sharma[†], Rachit Agarwal[†], Shashi Dhawan^{*}, Naresh Bansal[†], Vikas Singla[†],
Ashish Kumar[†], Anil Arora[†]

^{*}Department of Gastroenterology and Pathology, Sir Ganga Ram Hospital, New Delhi, India and [†]Sir Ganga Ram Hospital, New Delhi, India

Background: Non-cirrhotic portal hypertension (NCPH) is a common cause of variceal bleed in developing countries. Transient elastography (TE) using Fibroscan is a useful technique for evaluation of fibrosis in patients with liver disease. There is a paucity of studies evaluating TE in patients with Non-cirrhotic portal fibrosis (NCPF) and none in Asian population. Aim of this study was to evaluate role of TE in NCPF. **Methods:** Retrospective data of consecutive patients of NCPF as per Asian Pacific Association for the Study of Liver (APASL) guidelines were noted. All patients had liver biopsy, TE, computed tomography of abdomen and hepatic venous pressure gradient (HVPG). Twenty age and gender matched healthy subjects and forty age matched patients with cirrhosis with Child's A were taken as controls. **Results:** A total of 20 patients with age [median 29.5 (13–50) years], Male:Female = 11:9 with a diagnosis of NCPF were enrolled from January 2011 to December 2015. Of 20 patients 18 patients had variceal bleed and required endoscopic band ligation. There was no difference in haemoglobin and platelet count between patients with cirrhosis and NCPF, but total leucocyte count was significantly lower in patients with NCPF compared to patients with cirrhosis (3.2 vs $6.7 \times 10^3/\text{cumm}$, $P = 0.01$). TE (Fibroscan) was high in patients with NCPF compared to healthy controls (6.8 vs 4.7 kPa, $P = 0.001$) but it was significantly low compared to cirrhotic patients (6.8 vs 52.3 kPa, $P = 0.001$). HVPG is significant low in patients with NCPF compared to patients with cirrhosis (5.0 vs 16.0 mmHg, $P = 0.001$). **Conclusion:** Transient elastography (Fibroscan) is significantly low in patients with NCPF compared to patients with cirrhosis. It is a very useful non-invasive technique to differentiate between Child's A cirrhosis and non-cirrhotic portal fibrosis. (J CLIN EXP HEPATOL 2017;7:230–234)

Non-cirrhotic Portal Fibrosis (NCPF) also called as Idiopathic portal hypertension (IPH), is a disorder of unknown aetiology. It is clinically characterised by features of portal hypertension (PHT); moderate to massive splenomegaly, with or without hypersplenism, preserved liver functions, and patent hepatic and portal veins on radiological imaging.¹ The disease has been reported both from developing and developed countries.^{2,3} According to the consensus statement of the Asian Pacific Association for the Study of the Liver (APASL) on NCPF, the disease accounts for approximately 10–30% of all cases of variceal bleed in several parts of the world including India.⁴

Portal hypertension is defined by a portal-caval venous pressure gradient exceeding 5 mm Hg.¹ Cirrhosis is the leading cause of PHT all over the world. However in many

developing countries non-cirrhotic portal hypertension (NCPH) is seen in 10–30% of patients with PHT. The majority of NCPF patients present with signs or complications of portal hypertension.^{2–4} In Indian subcontinent two third of patients with NCPF presented with gastrointestinal haemorrhage, in contrast, a low prevalence of upper gastrointestinal bleeding as an initial manifestation has been reported in Japanese and Western patients, of which the majority presented with splenomegaly.^{5,6}

Prognosis of patient with variceal bleed differs in patient with NCPH compared to patients with cirrhosis. Radiological and biochemical tests are often done to evaluate of patients of variceal bleed.^{7,8} However they are non-contributory in some patients and liver biopsy or hepatic venous pressure gradient is done to know fibrosis of liver and degree of portal hypertension. Due to invasive nature of these procedures, patient acceptability is limited. So to differentiate Child Pugh Class A and NCPF is often a problem in clinical practice.

Liver stiffness (LS) measurement by transient elastography (TE) is a very promising non-invasive method for the diagnosis of fibrosis in chronic liver diseases.^{9–11} A strong correlation between LS measurements and liver fibrosis stages, assessed by simultaneous liver biopsies, have been reported in chronic hepatitis B, C and non-alcoholic steatohepatitis (NASH). There is no data on TE (Fibroscan) in

Keywords: NCPF, transient elastography, fibroscan

Received: 4.07.2016; **Accepted:** 1.03.2017; **Available online:** 14 March 2017

Address for correspondence: Sir Ganga Ram Hospital, New Delhi, India.

Abbreviations: APASL: Asian Pacific Association for the Study of Liver; EVL: endoscopic variceal ligation; FHVP: free hepatic venous pressure; HVPG: hepatic venous pressure gradient; IPH: idiopathic portal hypertension; IQR: interquartile range; LS: liver stiffness; NCPF: non-cirrhotic portal fibrosis; PHT: portal hypertension; SR: success rate; TE: transient elastography; TM: time motion; WHVP: wedged (occluded) hepatic venous pressure

<http://dx.doi.org/10.1016/j.jceh.2017.03.002>




Figure 1 Box Plot diagram showing Transient elastography in patients with cirrhosis, controls and non-cirrhotic portal fibrosis.

patients with NCPF. The aim of this study was to evaluate the role of TE (Fibroscan) in differentiating patients with NCPF and Cirrhosis with Child Pugh class A (Figure 1).

MATERIALS AND METHODS

Patient Characteristics

This is a retrospective study of patients which included patients diagnosed with NCPF between January 2011 to December 2015. This study was approved by the Institutional Review Board of our Hospital. Consecutive patients of NCPF were included during this period. Patients were diagnosed as NCPF on basis of liver biopsy according to APASL recommendations.⁴ Patients were excluded if they had associated hepatitis B, C, history of alcohol intake, patients with jaundice and portal biliopathy and any shunt surgery in the past.

Twenty healthy subjects were taken as control. All these controls were asymptomatic and were screened to rule out underlying liver disease based on normal ultrasound abdomen, normal liver function tests and negative serology for hepatitis B and C. Similarly, for inclusion of cirrhotic patients, retrospective data (from January 2011 to December 2015) was analysed. All patients were age matched and belonged to Child Pugh class A. All were confirmed liver cirrhosis on basis of liver biopsy and had undergone a TE (fibroscan) and HVPg. Patients who had active alcohol consumption in last 6 months, had HCC or portal vein thrombosis were excluded from the study.

Liver Stiffness Measurement by Fibroscan and Hepatic Venous Pressure Gradient (HVPg)

TE was performed by hepatologist with 5 years of experience and who had performed more than 1500 fibroscans

using the FibroScan apparatus (Echosens, Paris, France), which consists of a 5-MHz ultrasound transducer probe mounted on the axis of a vibrator. The tip of the transducer (M-probe) was covered with a drop of gel and placed perpendicularly in the intercostal space with the patient lying in dorsal decubitus position with the right arm in the maximal abduction. Under control one in time motion (TM) and A-mode, the operator chose a liver portion within the right liver lobe at least 6 cm thick, free of large vascular structures and gallbladder. The median value of 10 successful acquisitions, expressed in kilopascal (kPa), was kept as representative of the LS measurement. LS failure was recorded when no value was obtained after at least 10 shots. The results were considered unreliable in the following circumstances: valid shots fewer than 10, success rate (SR) less than 60%, or interquartile range (IQR)/LS greater than 30%.⁸

HVPg Measurement

HVPg was measured after an overnight fast and haemodynamic assessment were carried out using standard procedure. Briefly, under local anaesthesia and in supine position, a venous introducer was placed in the right femoral vein by the Seldinger technique. Under fluoroscopic guidance, a 7F balloon-tipped Swan Ganz catheter (Boston Scientific, Massachusetts, USA) was introduced in to the main right hepatic vein. Free hepatic venous pressure (FHVP) and wedged (occluded) hepatic venous pressure (WHVP) were measured using Nihon Kohden (Tokyo, Japan) haemodynamic monitor with pressure transducers. Measurements were made in triplicate, and the mean of three readings was taken in each case. If there was a difference of more than 1 mmHg between the readings, all the readings were repeated. Hepatic venous pressure gradient (HVPg) was obtained as the difference between WHVP and FHVP.¹²

Blood Tests, Imaging and Biochemical Examinations

Patient venous blood was taken and analysed for routine liver function tests and hematologic parameters by conventional methods and evaluation of viral markers like hepatitis B and hepatic C. All patients had ultrasound abdomen along with Doppler study for splenoportal axis and computed tomography (triple phase) for liver and spleen size. All patients had liver biopsy which was analysed by two pathologists who had vast experience in the field of liver histology. All patients had upper gastrointestinal endoscopy for evaluation of varices.

Statistical Analysis and Data Management

Data processing was performed by using the software packages SPSS. For a comparison of categorical variables, chi square and Fisher's exact tests were used, and for continuous variables, a Mann-Whitney test for unpaired

Download English Version:

<https://daneshyari.com/en/article/5664847>

Download Persian Version:

<https://daneshyari.com/article/5664847>

[Daneshyari.com](https://daneshyari.com)